YEWB — Yew Bio-Pharm Share Price
- $0.01m
- $8.98m
- $27.31m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0 | ||
Price to Tang. Book | 0.01 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0 | ||
EV to EBITDA | 2.33 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.13% | ||
Return on Equity | 0.89% | ||
Operating Margin | 3.57% |
Financial Summary
Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 51.35 | 40.54 | 37.6 | 27.88 | 27.31 | n/a | n/a | -1.58% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -61.84 | +53.97 | n/a | n/a | +48.79 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Yew Bio-Pharm Group, Inc. is a grower and seller of yew trees. The Company is engaged in manufacturing and sale of products made from yew trees and branches and leaves of yew trees for the manufacture of traditional Chinese medicine (TCM) containing taxol. The Company’s segments include PRC and USA. The PRC segment manages and reviews the business of Harbin Yew Science and Technology Development Co., Ltd. (HDS), Heilongjiang Jinshangjing Bio-Technology Development Co., Limited (JSJ), Harbin Yew Food Co., Ltd (HYF) and Yew (Guangzhou) Bio-Technology Co., Ltd (YBT). The USA segment manages and reviews the business of Yew Bio-Pharm (HK), and MC Commerce Holding Inc. (MC). The Company’s products include yew seedling products and yew handicraft products such as yew candles, yew essential oil soap, pine needle extract, complex taxus cuspidate extract, and composite northeast yew extract.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- November 5th, 2007
- Public Since
- December 18th, 2007
- No. of Employees
- 41
- Sector
- Paper & Forest Products
- Industry
- Basic Materials
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 51,700,000

- Address
- 9460 Telstar Avenue, Suite 6, EL MONTE, 91731
- Web
- http://www.yewchina.com/
- Phone
- +1 6264019588
- Auditors
- Simon & Edward LLP
Upcoming Events for YEWB
Similar to YEWB
Amazonas Florestal
Pink Sheets on Nasdaq
Arrow Resources Development
Pink Sheets on Nasdaq
BPM
Pink Sheets on Nasdaq
Biomass Secure Power
Pink Sheets on Nasdaq
Blue Star Opportunities
Pink Sheets on Nasdaq
FAQ
As of Today at 18:25 UTC, shares in Yew Bio-Pharm are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Yew Bio-Pharm last closed at $0.00 and the price had moved by +100% over the past 365 days. In terms of relative price strength the Yew Bio-Pharm share price has outperformed the S&P500 Index by +76.54% over the past year.
There is no consensus recommendation for this security.
Find out moreYew Bio-Pharm does not currently pay a dividend.
Yew Bio-Pharm does not currently pay a dividend.
Yew Bio-Pharm does not currently pay a dividend.
To buy shares in Yew Bio-Pharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Yew Bio-Pharm had a market capitalisation of $0.01m.
Here are the trading details for Yew Bio-Pharm:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: YEWB
Based on an overall assessment of its quality, value and momentum Yew Bio-Pharm is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yew Bio-Pharm. Over the past six months, its share price has underperformed the S&P500 Index by -80.2%.
As of the last closing price of $0.00, shares in Yew Bio-Pharm were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yew Bio-Pharm PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Yew Bio-Pharm's management team is headed by:
- Guifang Qi - CHM
- Xingming Han - OTH
- Yongchun Shi - IND
- Liu Xiefeng - IND